A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Purpose
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Condition
- Hidradenitis Suppurativa
Eligibility
- Eligible Ages
- Between 12 Years and 100 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male and female participants ≥ 12 years of age at the time of signing of the informed consent. 2. Diagnosis of HS based on clinical history and physical examination for at least 6 months prior to the Baseline visit. 3. Participants with moderate to severe HS defined as: - A total of at least 5 AN count (abscesses and/or inflammatory nodules) AND - Inflammatory lesions should affect at least 2 distinct anatomic areas (e.g., left and right axillae)
Exclusion Criteria
- Presence of more than 20 fistulae/tunnels (both draining and non-draining) in total at baseline. 2. Any active skin disease or conditions that may interfere with the assessment of HS. 3. Previous exposure to remibrutinib or other BTK inhibitors. 4. Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days (for small molecules) prior to randomization, or until the pharmacodynamic effect has returned to baseline (for biologics), whichever is longer. 5. Significant bleeding risk or coagulation disorders. 6. History of gastrointestinal bleeding. 7. Requirement for anti-platelet (except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d) or anti-coagulant medication. 8. History or current hepatic disease. 9. Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the Investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant. 10. History of hypersensitivity to any of the study drug constituents. 11. Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the trial as per investigator's assessment. These infectious diseases include and are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected Human Immunodeficiency Virus (HIV) infection. Should it be required by local regulations and/or considered appropriate by the investigator, an HIV test can be performed to confirm eligibility. 12. History of live attenuated vaccine administration within 6 weeks prior to randomization or requirement to receive these vaccinations at any time while on study treatment. 13. Major surgery within 8 weeks prior to screening or planned surgery for the duration of the study. Other protocol-defined inclusion/exclusion criteria may apply.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Remibrutinib Dose A (Treatment Period 1 and 2) |
Participants randomized to receive remibrutinib Dose A during Treatment Period 1 and 2 |
|
|
Experimental Remibrutinib Dose B (Treatment Period 1 and 2) |
Participants randomized to receive remibrutinib Dose B during Treatment Period 1 and 2 |
|
|
Placebo Comparator Placebo (Treatment Period 1) + remibrutinib Dose B (Treatment Period 2) |
Participants randomized to receive placebo during Treatment Period 1 followed by remibrutinib dose B during Treatment Period 2 |
|
Recruiting Locations
Medical Dermatology Specialists
Phoenix, Arizona 85006
Phoenix, Arizona 85006
Johnson Dermatology
Fort Smith, Arkansas 72916
Fort Smith, Arkansas 72916
Arkansas Research Trials
North Little Rock, Arkansas 72117
North Little Rock, Arkansas 72117
Olive View UCLA Medical Center
Sylmar, California 91342
Sylmar, California 91342
Clinical Trials Research Institute
Thousand Oaks, California 91320
Thousand Oaks, California 91320
Howard University College of Medicine
Washington D.C., District of Columbia 20060
Washington D.C., District of Columbia 20060
Florida Academic Centers Research and Education LLC
Coral Gables, Florida 33134
Coral Gables, Florida 33134
University of MiamiHealth System
Miami, Florida 33125
Miami, Florida 33125
Ziaderm Research LLC
North Miami Beach, Florida 33162
North Miami Beach, Florida 33162
Revival Research Institute LLC
Evans, Georgia 30809
Evans, Georgia 30809
Gwinnett Clinical Research Center
Snellville, Georgia 30078
Snellville, Georgia 30078
Immunology-Rheumatology Research
Suwanee, Georgia 30024
Suwanee, Georgia 30024
Illinois Dermatology Institute
Chicago, Illinois 60602
Chicago, Illinois 60602
Dawes Fretzin Clinical Rea Group
Indianapolis, Indiana 46256
Indianapolis, Indiana 46256
Dermat. and Adv. Aesthetics
Lake Charles, Louisiana 70605
Lake Charles, Louisiana 70605
Michigan Center for Rsrch Company
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Henry Ford Hospital
Detroit, Michigan 48202-2689
Detroit, Michigan 48202-2689
University of Mississippi Med Ctr
Jackson, Mississippi 39216
Jackson, Mississippi 39216
Care Access Hoboken
Hoboken, New Jersey 07030
Hoboken, New Jersey 07030
Icahn School Of Med At Mount Sinai
New York, New York 10029
New York, New York 10029
Skinsearch of Rochester Inc
Rochester, New York 14623
Rochester, New York 14623
OnSite Clinical Solutions LLC
Huntersville, North Carolina 28078
Huntersville, North Carolina 28078
Wake Forest Baptist Health
Winston-Salem, North Carolina 27104
Winston-Salem, North Carolina 27104
Unity Clinical Research
Oklahoma City, Oklahoma 73118
Oklahoma City, Oklahoma 73118
Essential Medical Research
Tulsa, Oklahoma 74137
Tulsa, Oklahoma 74137
UP Medical Center H System
Pittsburgh, Pennsylvania 15213-3403
Pittsburgh, Pennsylvania 15213-3403
Medical University of South Carolina MUSC
Charleston, South Carolina 29425
Charleston, South Carolina 29425
Advanced Research Experts
Nashville, Tennessee 37211
Nashville, Tennessee 37211
Bellaire Dermatology Associates
Bellaire, Texas 77401
Bellaire, Texas 77401
RFSA Dermatology
San Antonio, Texas 78213
San Antonio, Texas 78213
More Details
- NCT ID
- NCT06799000
- Status
- Recruiting
- Sponsor
- Novartis Pharmaceuticals
Detailed Description
The total duration of the study is 76 weeks and consists of: Screening (up to 4 weeks), Treatment Period 1 (16 weeks, double-blind treatment with remibrutinib (Dose A or Dose B) or placebo, Treatment Period 2 (52 weeks, treatment with remibrutinib (Dose A or Dose B) and Safety Follow-Up (treatment-free follow-up for 4 weeks). Participants who prematurely discontinue study treatment (either during Treatment Period 1 or Treatment Period 2) are encouraged to remain in the study. Participants who do not wish to remain in the study will enter a 4-week Safety Follow-Up period.